Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

Diabetes Care

Volumn 24, Issue 4, 2001, Pages 710-719

  Miyazaki, Yoshinori ^a   Mahankali, Archana ^a   Matsuda, Masafumi ^a   Glass, Leonard ^a   Mahankali, Srikanth ^a   Ferrannini, Eleuterio ^a   Cusi, Kenneth ^a   Mandarino, Lawrence J ^a   DeFronzo, Ralph A ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOSE; INSULIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIVER; MALE; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034833667     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.4.710     Document Type: Article

References (43)

1. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes
2. Banting lecture: Role of insulin resistance in human disease
3. Impaired glucose tolerance as a disorder of insulin action longitudinal and cross-sectional studies in Pima Indians
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS)
5. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes
6. Pharmacologic therapy for type 2 diabetes mellitus
7. Efficacy of metformin in patients with on-insulin dependent diabetes mellitus
8. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
9. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
10. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes
11. Glucose transport deficiency in diabetic animals is corrected by treatment with oral antihyperglycemic agent pioglitazone
12. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys
13. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
14. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
15. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women
16. Glucose clamp technique: A method for quantifying insulin secretion and resistance
17. Influence of glucose loading and of injected insulin on hepatic glucose output
18. Relationship between total body water and surface area in normal and obese subjects
19. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: A twelve week, randomized, placebo-controlled study
20. Contributions of gluconeogenesis to glucose production in the fasted state
21. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp
22. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials: The Glipizide Gastrointestinal Therapeutic System Study Group
23. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
24. Effect of troglitazone on body fat distribution in type 2 diabetic patients
25. Reciprocal variation in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance
26. Studies on the mass action effect of glucose in diabetes: Evidence for glucose resistance
27. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange
28. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus
29. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus
30. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake
31. In vitro studies on the action of CS-045, a new antidiabetic agent
32. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM
33. The effect of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects
34. Effect of fatty acids on glucose production and utilization in humans
35. High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus
36. 13C-nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic patients
37. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
38. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
39. Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rats
40. Troglitazone increases the number of small adipocytes without change of white adipose tissue mass in obese Zucker rats
41. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
42. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
43. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women